Perhaps today's announcement happens out of the blue. But I believe Moses had this solid succession planning in place for a long time.
If you think about it, the company is primarily focused on antisense drugs for rare diseases.
So, why hired Dr. Charmaine Gittleson and not other candidates? (see the ASX announcement on 22-03-2021 about her qualification).
Then why hired her as an Non-Executive Director in the first place? I guess she has now passed the so-called "3-months" probation period.
Based on her extensive experience/expertise in rare diseases, no doubt she can brings new perspectives and ideas, new mindset and energy that support the company's vision, growth and advancement. I believe she and the teams will bring this company to the next level.
As I mentioned earlier, 2021 is a transformational year for ANP! The next 6 months is going to be exciting as per the announcement.
Perhaps today's announcement happens out of the blue. But I...
-
- There are more pages in this discussion • 90 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |